American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, ...
American Academy of Dermatology7h
American Academy of Dermatology statement on Benzoyl Peroxide in OTC Personal Care Products
American Academy of Dermatology President Seemal R. Desai, MD, FAAD ...
Managed Healthcare Executive6h
Improving Diagnosis and Treatment for Hidradenitis Suppurativa | AAD 2025
American Academy of Dermatology (AAD) meeting, Steven Daveluy, M.D., associate professor and program director of dermatology ...
The American Journal of Managed Care12h
Climate Change, Pollution’s Growing Impact on Dermatology
Experts stressed the importance of dermatologists engaging in climate advocacy and adopting sustainable practices, as their ...
Managed Healthcare Executive13h
Study Finds Opzelura Used As-Needed Improves Quality of Life | AAD 2025
The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...
The American Journal of Managed Care13h
Late-Breaking Data at AAD on Topical Ruxolitinib Show Itch Relief in Atopic Dermatitis, Prurigo Nodularis
Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...
AMERICAN ACADEMY OF DERMATOLOGY INSTALLS NEW OFFICERS, BOARD MEMBERS
Four new officers and four new board members will be installed immediately upon conclusion of the 2025 Annual Meeting of the American Academy of Dermatology. The officers and board members are all ...
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of ...
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
Journey Medical plans to highlight the launch of Emrosi™ and showcase its line of prescription dermatology products. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in ...